Pfenex (PFNX) News Today $12.75 0.00 (0.00%) (As of 10/1/2020) Add Compare Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period NKY Medical Holdings Ltd Class A 300109January 31, 2024 | morningstar.comLigand Pharmaceuticals: Struggling Along (NASDAQ:LGND) - Seeking AlphaSeptember 25, 2022 | seekingalpha.comForte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update - Business WireAugust 15, 2022 | businesswire.comLigand Reports Second Quarter 2022 Financial Results - Business WireAugust 9, 2022 | businesswire.com2022-08-08 | NDAQ:LGND | Press Release | Ligand Pharmaceuticals Incorporated - StockhouseAugust 8, 2022 | stockhouse.comOsteoporosis Therapeutics Market to Top US$ 14 Bn Valuation by 2026: Fact.MR Analysis - Yahoo FinanceMay 17, 2022 | finance.yahoo.comLigand Reports First Quarter 2022 Financial Results - StreetInsider.comMay 5, 2022 | streetinsider.comLigand Reports First Quarter 2022 Financial Results - Marketscreener.comMay 4, 2022 | marketscreener.comLigand Pharmaceuticals: Moving Parts Keep Moving - Seeking AlphaMarch 29, 2022 | seekingalpha.comGlobal Pharma, Biotech and Diagnostics Joint Venture Partnering Deal Terms and Agreements Analysis Report 2021 with Example Case Studies of Agila Specialties/Pfenex and Dance Biopharm/Harmony Asset - PR NewswireMarch 24, 2022 | prnewswire.comLigand Reports Fourth Quarter and Full Year 2021 Financial Results - Business WireFebruary 17, 2022 | businesswire.comPipeline Therapeutics Appoints Eef Schimmelpennink to its Board of Directors - Business WireFebruary 15, 2022 | businesswire.comLIGAND PHARMACEUTICALS INC : Termination of a Material Definitive Agreement (form 8-K) - marketscreener.comJanuary 14, 2022 | marketscreener.comDr. Hubert Chen Joins ADARx Pharmaceuticals as Chief Medical Officer - Business WireJanuary 5, 2022 | businesswire.comSolid Nutrition Unit to Aid Archer Daniels (ADM) Amid Cost Woes - NasdaqNovember 10, 2021 | nasdaq.comDare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates - NasdaqNovember 10, 2021 | nasdaq.comfuboTV Falls 7% Despite Solid Q3 Results - NasdaqNovember 10, 2021 | nasdaq.comLIGAND PHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) - marketscreener.comNovember 9, 2021 | marketscreener.comLigand Reports Third Quarter 2021 Financial Results - Business WireNovember 9, 2021 | businesswire.comGlobal Joint Venture Partnering Deals Report/Directory 2021: Trends, Players and Financials 2014-2021 - B - BenzingaSeptember 23, 2021 | benzinga.comOphthalmology Biosimilars Market Report 2028 | Size, Share, Growth, Trends, Competitive Landscape, Revenue, Forecast - Yahoo FinanceSeptember 7, 2021 | yahoo.comLigand Pharmaceuticals Incorporated (LGND) Q2 2021 Earnings Call Transcript - Motley FoolJuly 30, 2021 | fool.comLigand Reports Second Quarter 2021 Financial Results - Business WireJuly 29, 2021 | businesswire.com Get Pfenex News Delivered to You Automatically Sign up to receive the latest news and ratings for PFNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED. Click here to see the details because I believe a lot of people will get rich. PFNX Media Mentions By Week PFNX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PFNX News Sentiment▼0.000.59▲Average Medical News Sentiment PFNX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PFNX Articles This Week▼00▲PFNX Articles Average Week Get Pfenex News Delivered to You Automatically Sign up to receive the latest news and ratings for PFNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies XNCR News EVO News ARQT News RCUS News NRIX News EVTCY News KNSA News IMCR News OCUL News MESO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:PFNX) was last updated on 12/23/2024 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pfenex Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pfenex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
